VACC Vaccibody AS

Nykode Therapeutics - Quarterly report Q1 2024

Nykode Therapeutics - Quarterly report Q1 2024

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024.

The financial report can be accessed in the Investors section of the Company’s website: .

The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link:

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at .

Contact:

Alexandra Deschner, Head of IR

Nykode Therapeutics ASA

Nykode Therapeutics ASA

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

A PDF attachment accompanying this announcement is available at: 



EN
14/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaccibody AS

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
 PRESS RELEASE

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform ...

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona. The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly...

Geir Hiller Holom
  • Geir Hiller Holom

Nykode Therapeutics (Buy, TP: NOK21.00) - It’s all about the partners

Following the decision to discontinue the C-04 trial, we expect limited value from data within the guided runway. We continue to like the technology’s outlook and believe partnerships could create material shareholder value short- to mid-term. We reiterate our BUY, but have cut our target price to NOK21 (31).

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
Geir Hiller Holom
  • Geir Hiller Holom

Nykode Therapeutics (Buy, TP: NOK31.00) - Q2 report and C-04 discontin...

The company announced it has decided to discontinue the C-04 trial based on standard-of-care changes and feedback from key opinion leaders. Regarding the recently announced Genentech reorganisation, it said that it has “not received any indications of the partnership being affected”.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch